Drug Profile
Cenerimod - Idorsia Pharmaceuticals
Alternative Names: ACT-334441; Second selective S1P1 receptor agonist - IdorsiaLatest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Developer Idorsia Pharmaceuticals
- Class Oxadiazoles; Pyridines; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Systemic lupus erythematosus
- Preclinical Rheumatoid arthritis
- No development reported Autoimmune disorders
Most Recent Events
- 28 Feb 2024 Viatris and Idorsia entered into licensing agreement for the development and commercialisation of two phase III assets of cenerimod
- 10 Nov 2023 Pharmacodynamics data from preclinical trial in Systemic lupus erythematosus presented at the ACR Convergence 2023 (ACR-2023)
- 10 Nov 2023 Preclinical trials in Rheumatoid arthritis in Switzerland (PO) before November 2023